Triple drug cocktail shows promise against tough lung cancer
NCT ID NCT03377023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first finds the safest dose, and the second measures how many patients respond. The goal is to see if this triple therapy can control the disease better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, ipilimumab, and nintedanib
What this could lead to
If it works, this could offer a new treatment option for people with advanced non-small cell lung cancer who have few choices left.
What could go wrong
This is an early-phase trial with only 66 participants, so results may not apply to everyone. The three-drug combination may cause significant side effects, and it's not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States